PulmoGeniX™ Technologies and the Mayo Clinic have a joint development relationship to commercialize significant innovations to treat and cure the most severe cases of asthma.



The PulmoGeniX system is a first-in-kind suite of diagnostic and therapeutic tools for Bronchial Smooth Muscle Modification Therapy. 

Severe Asthma Attack


The acute, chronic asthma patient population is represented by more than 2 million severe asthma patients in the U.S. and 8 million worldwide

Previous Next

Dr. Jerry Katzman, MD

Dr. Jerry Katzman, CEO of PulmoGeniX

“In the spirit of collaboration, PulmoGeniX, Inc. and the Mayo Clinic combine their respective technologies and expertise to advance treatment and control of asthma for patients whose asthma is persistent and not well controlled.  We expect to commercialize a next generation procedure that incorporates diagnostic intelligence before and after treatment in a safe, cost effective solution.  We welcome Mayo Clinic’s participation and development, clinical investigation and study of the technology.”
 — Dr. Jerry Katzman, CEO